Predictive Value of Preoperative Endoscopic Ultrasound (EUS) After Neoadjuvant Chemotherapy in Locally Advanced Esophagogastric Cancer – Data From a Randomized German Phase II Trial

Abstract

Purpose The role of EUS before or after neoadjuvant chemotherapy (nCTX) in advanced esophagogastric cancer (EGC) is still unclear. The phase II NEOPECX trial evaluated perioperative chemotherapy with or without panitumumab in this setting. The aim of this sub-study was to investigate the prognostic value of EUS-guided preoperative staging before and after nCTX.

Materials and Methods Preoperative yuT/yuN stages by EUS were compared with histopathological ypT/ypN stages after curative resection. Reduction in T-stage from baseline to preoperative EUS was defined as downstaging (DS+) and compared to progression-free (PFS) and overall survival (OS) of patients without downstaging (DS-). In addition, preoperative EUS N-stages (positive N+ or negative N-) were correlated with clinical data.

Results The preoperative yuT-stage correlated with the ypT-stage in 48% of cases (sensitivity 48%, specificity 52%), while the preoperative yuN-stage correlated with the ypN-stage in 64% (sensitivity 76%, specificity 52%). Within DS+ patients who were downstaged by ≥ 2 T-categories, a trend towards improved OS was detected (median OS DS+: not reached (NR), median OS DS-: 38.5 months (M), p=0.21). Patients with yuN+ at preoperative EUS had a worse outcome than yuN- patients (median OS yuN-: NR, median OS yuN+: 38.5 M, p = 0.013).

Conclusion The diagnostic accuracy of EUS to predict the response after nCTX in patients with advanced EGC is limited. In the current study the endosonographic detection of lymph node metastasis after nCTX indicates a poor prognosis. In the future, preoperative EUS with sectional imaging procedures may be used to tailor treatment for patients with advanced EGC.

Zusammenfassung

Ziel Die Rolle des endoskopischen Ultraschalls (EUS) vor oder nach neoadjuvanter Chemotherapie (nCTX) bei fortgeschrittenem ösophagogastrischem Karzinom (EGC) ist noch unklar. Die Phase-II-Studie NEOPECX untersuchte die perioperative Chemotherapie mit und ohne Panitumumab in diesem Zusammenhang. Ziel dieser Teilstudie war es, den prognostischen Wert des EUS-gestützten präoperativen Stagings vor und nach nCTX zu untersuchen.

Material und Methoden Das präoperative yuT/yuN-Stadium mittels EUS wurde mit dem histopathologischen ypT/ypN-Stadium nach kurativer Resektion verglichen. Die Reduktion des T-Stadiums vom Ausgangswert bis zum präoperativen EUS wurde als Downstaging (DS+) definiert und mit dem progressionsfreien Überleben (PFS) und dem Gesamtüberleben (OS) von Patienten ohne Downstaging (DS-) verglichen. Darüber hinaus wurden die präoperativen EUS-N-Stadien (positives N+ oder negatives N-) mit den klinischen Daten korreliert.

Ergebnisse Das präoperative yuT-Stadium korrelierte in 48% mit dem ypT-Stadium (Sensitivität 48%, Spezifität 52%), während das präoperative yuN-Stadium in 64% mit dem ypN-Stadium korrelierte (Sensitivität 76%, Spezifität 52%). Bei DS+-Patienten mit Downstaging um ≥2 T-Kategorien wurde ein Trend zu einem verbesserten OS festgestellt (medianes OS DS+: nicht erreicht (NR), medianes OS DS-: 38,5 Monate (M), p=0,21). Patienten mit yuN+ beim präoperativen EUS hatten einen schlechteren Outcome als yuN-Patienten (medianes OS yuN-: NR, medianes OS yuN+: 38,5 M, p=0,013).

Schlussfolgerung Die diagnostische Genauigkeit des EUS zur Vorhersage des Ansprechens nach nCTX bei Patienten mit fortgeschrittenem EGC ist begrenzt. In der aktuellen Studie deutet der endosonografische Nachweis von Lymphknotenmetastasen nach nCTX auf eine schlechte Prognose hin. In Zukunft könnte der präoperative EUS mit Schnittbildverfahren dazu dienen, die Behandlung von Patienten mit fortgeschrittenem EGC abzustimmen.

Keywords

Mortality - Locally advanced esophagogastric cancer - Endosonography - THEMES - staging

Publication History

Received: 12 November 2020

Accepted after revision: 24 August 2021

Article published online:
28 February 2022

• References

• 1 Abdalla EK, Pisters PW. Staging and preoperative evaluation of upper gastrointestinal malignancies. Semin Oncol 2004; 31: 513-529 DOI: 10.1053/j.seminoncol.2004.04.014. (PMID: 15297943)
• 2 Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol 2007; 25: 2107-2116 DOI: 10.1200/jco.2006.09.5224. (PMID: 17513817)
• 3 Weber WA, Ott K. Imaging of esophageal and gastric cancer. Semin Oncol 2004; 31: 530-541 DOI: 10.1053/j.seminoncol.2004.04.016. (PMID: 15297944)
• 4 Ajani JA, D'Amico TA, Almhanna K. et al. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2016; 14: 1286-1312 DOI: 10.6004/jnccn.2016.0137. (PMID: 27697982)
• 5 Cunningham D, Allum WH, Stenning SP. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20 DOI: 10.1056/NEJMoa055531. (PMID: 16822992)
• 6 Ychou M, Boige V, Pignon JP. et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-1721 DOI: 10.1200/jco.2010.33.0597. (PMID: 21444866)
• 7 Al-Batran SE, Homann N, Pauligk C. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393: 1948-1957 DOI: 10.1016/s0140-6736(18)32557-1. (PMID: 30982686)
• 8 Smyth EC, Verheij M, Allum W. et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: v38-v49 DOI: 10.1093/annonc/mdw350. (PMID: 27664260)
• 9 Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association [Anonym]. 2017; 20: 1-19 DOI: 10.1007/s10120-016-0622-4.
• 10 Smyth EC, Fassan M, Cunningham D. et al. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. J Clin Oncol 2016; 34: 2721-2727 DOI: 10.1200/jco.2015.65.7692. (PMID: 27298411)
• 11 Moehler M, Al-Batran SE, Andus T. et al. German S3-guideline "Diagnosis and treatment of esophagogastric cancer". Z Gastroenterol 2011; 49: 461-531 DOI: 10.1055/s-0031-1273201. (PMID: 21476183)
• 12 Stahl M, Maderer A, Lordick F. et al. Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801). European journal of cancer (Oxford, England: 1990) 2018; 93: 119-126 DOI: 10.1016/j.ejca.2018.01.079. (PMID: 29501977)
• 13 Guo T, Yao F, Yang AM. et al. Endoscopic ultrasound in restaging and predicting pathological response for advanced gastric cancer patients after neoadjuvant chemotherapy. Asia Pac J Clin Oncol 2014; 10: e28-32 DOI: 10.1111/ajco.12045. (PMID: 23279745)
• 14 Greally M, Agarwal R, Ilson DH. Optimal management of gastroesophageal junction cancer. Cancer 2019; 125: 1990-2001 DOI: 10.1002/cncr.32066. (PMID: 30973648)
• 15 van Hagen P, Hulshof MC, van Lanschot JJ. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084 DOI: 10.1056/NEJMoa1112088. (PMID: 22646630)
• 16 Martin-Romano P, Sola JJ, Diaz-Gonzalez JA. et al. Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer. Br J Cancer 2016; 115: 655-663 DOI: 10.1038/bjc.2016.252. (PMID: 27537382)
• 17 Jiang N, Deng JY, Ding XW. et al. Tumor volume as a prognostic factor was superior to the seventh edition of the pT classification in resectable gastric cancer. Eur J Surg Oncol 2015; 41: 315-322 DOI: 10.1016/j.ejso.2014.11.045. (PMID: 25601610)
• 18 Tang X, He Q, Qu H. et al. Post-therapy pathologic tumor volume predicts survival in gastric cancer patients who underwent neoadjuvant chemotherapy and gastrectomy. BMC Cancer 2019; 19: 797 DOI: 10.1186/s12885-019-6012-7. (PMID: 31409315)
• 19 van der Bogt RD, Noordman BJ, Krishnadath KK. et al. Endoscopic ultrasound measurements for detection of residual disease after neoadjuvant chemoradiotherapy for esophageal cancer. Endoscopy 2019; 51: 326-332 DOI: 10.1055/a-0795-3220. (PMID: 30497088)
• 20 Zhu Y, Sun Y, Hu S. et al. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China. BMC Gastroenterol 2017; 17: 41 DOI: 10.1186/s12876-017-0598-5. (PMID: 29202711)
• 21 Zhu YL, Sun YK, Xue XM. et al. Unnecessity of lymph node regression evaluation for predicting gastric adenocarcinoma outcome after neoadjuvant chemotherapy. World J Gastrointest Oncol 2019; 11: 48-58 DOI: 10.4251/wjgo.v11.i1.48. (PMID: 30984350)
• 22 Park SR, Lee JS, Kim CG. et al. Endoscopic ultrasound and computed tomography in restaging and predicting prognosis after neoadjuvant chemotherapy in patients with locally advanced gastric cancer. Cancer 2008; 112: 2368-2376 DOI: 10.1002/cncr.23483. (PMID: 18404697)
• 23 Mesenas S, Vu C, McStay M. et al. A large series, resection controlled study to assess the value of radial EUS in restaging gastroesophageal cancer following neoadjuvant chemotherapy. Dis Esophagus 2008; 21: 37-42 DOI: 10.1111/j.1442-2050.2007.00731.x. (PMID: 18197937)
• 24 Bohle W, Zachmann R, Zoller WG. Sequential endoscopic ultrasound identifies predictive variables for relapse-free follow-up after neoadjuvant chemotherapy in gastric cancer. Scand J Gastroenterol 2017; 52: 754-761 DOI: 10.1080/00365521.2017.1303845. (PMID: 28355948)
• 25 Jenssen C, Dietrich CF, Burmester E. Maligne Neoplasien des Verdauungstrakts – neue Aspekte zum endosonografischen Staging. Z Gastroenterol 2011; 49: 357-368 DOI: 10.1055/s-0029-1245870.
• 26 Jurgensen C, Brand J, Nothnagel M. et al. Prognostic relevance of gastric cancer staging by endoscopic ultrasound. Surg Endosc 2013; 27: 1124-1129 DOI: 10.1007/s00464-012-2558-z. (PMID: 23052533)
• 27 Beseth BD, Bedford R, Isacoff WH. et al. Endoscopic ultrasound does not accurately assess pathologic stage of esophageal cancer after neoadjuvant chemoradiotherapy. Am Surg 2000; 66: 827-831
• 28 Gertsen EC, de Jongh C, Brenkman HJF. et al. The additive value of restaging-CT during neoadjuvant chemotherapy for gastric cancer. Eur J Surg Oncol 2020; 46: 1247-1253 DOI: 10.1016/j.ejso.2020.04.002. (PMID: 32349895)
• 29 Redondo-Cerezo E, Martinez-Cara JG, Jimenez-Rosales R. et al. Endoscopic ultrasound in gastric cancer staging before and after neoadjuvant chemotherapy. A comparison with PET-CT in a clinical series. United European Gastroenterol J 2017; 5: 641-647 DOI: 10.1177/2050640616684697. (PMID: 28815027)
• 30 Yoshikawa T, Tanabe K, Nishikawa K. et al. Accuracy of CT staging of locally advanced gastric cancer after neoadjuvant chemotherapy: cohort evaluation within a randomized phase II study. Ann Surg Oncol 2014; 21 (03) S385-389 DOI: 10.1245/s10434-014-3615-8. (PMID: 24595801)
• 31 Wang YK, Shan F, Ying XJ. et al. Accuracy comparision of abdominal enhanced CT and endoscopic ultrasound in the staging of gastric cancer after neoadjuvant chemotherapy: a post hoc analysis of a randomized clinical trial. Zhonghua Wai Ke Za Zhi 2020; 58: 614-618 DOI: 10.3760/cma.j.cn112139-20200114-00027. (PMID: 32727193)
• 32 Vallbohmer D, Holscher AH, Schneider PM. et al. [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. J Surg Oncol 2010; 102: 135-140 DOI: 10.1002/jso.21592. (PMID: 20648583)
• 33 Wang C, Guo W, Zhou M. et al. The Predictive and Prognostic Value of Early Metabolic Response Assessed by Positron Emission Tomography in Advanced Gastric Cancer Treated with Chemotherapy. Clin Cancer Res 2016; 22: 1603-1610 DOI: 10.1158/1078-0432.CCR-14-3235. (PMID: 26607599)
• 34 Gleeson FC, Kipp BR, Caudill JL. et al. False positive endoscopic ultrasound fine needle aspiration cytology: incidence and risk factors. Gut 2010; 59: 586-593 DOI: 10.1136/gut.2009.187765. (PMID: 20427392)
• 35 Levy MJ, Gleeson FC, Campion MB. et al. Prospective cytological assessment of gastrointestinal luminal fluid acquired during EUS: a potential source of false-positive FNA and needle tract seeding. Am J Gastroenterol 2010; 105: 1311-1318 DOI: 10.1038/ajg.2010.80. (PMID: 20197762)
• 36 Noordman BJ, Wijnhoven BPL, Lagarde SM. et al. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial. BMC Cancer 2018; 18: 142 DOI: 10.1186/s12885-018-4034-1. (PMID: 29409469)
• 37 NCT02551458 CgI.: Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy (Esostrate). 2015